FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

ALSO NOTED: Novartis licenses MedImmune vaccine IP; Rumor Mill: Dr. Reddy bids for Bradley; and much more...

Tools

> Rumor Mill: Generic drugmaker Dr. Reddy's Laboratories is said to have submitted a bid for U.S.-based Bradley Pharma. FiercePharma

> Novartis has licensed MedImmune's reverse genetics intellectual property. Novartis will use the IP to support development of vaccine strains for seasonal, pre-pandemic and pandemic influenza vaccines. Financial details of the deal were not disclosed. Release

> Precision Therapeutics, which makes tests to analyze tumor cells, is planning an $80.5 million IPO. Report

> Two Massachusetts General Hospital researchers describe a way of creating novel enzymes that, for the first time, do not require prior understanding of exactly how the enzymes work. FierceBioresearcher

> A group of neurologists have been studying the role a particular enzyme plays in creating memories, saying that blocking the enzyme could offer a new approach to treating post-traumatic stress disorders as well as chronic pain. FierceBioresearcher

And Finally... The FDA wants more detailed sunscreen labels. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about Novartis   MedImmune   genetics   Biotech IPO   Pandemic Influenza   Bradley Pharma   Precision Therapeutics   Dr. Reddy's